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Abstract
Background: Prion diseases are fatal neurodegenerative disorders whose pathogenesis mechanisms are not fully
understood. In this context, the analysis of gene expression alterations occurring in prion-infected animals represents a
powerful tool that may contribute to unravel the molecular basis of prion diseases and therefore discover novel
potential targets for diagnosis and therapeutics. Here we present the first large-scale transcriptional profiling of brains
from BSE-infected cynomolgus macaques, which are an excellent model for human prion disorders.
Results: The study was conducted using the GeneChip® Rhesus Macaque Genome Array and revealed 300 transcripts
with expression changes greater than twofold. Among these, the bioinformatics analysis identified 86 genes with
known functions, most of which are involved in cellular development, cell death and survival, lipid homeostasis, and
acute phase response signaling. RT-qPCR was performed on selected gene transcripts in order to validate the differential
expression in infected animals versus controls. The results obtained with the microarray technology were confirmed
and a gene signature was identified. In brief, HBB and HBA2 were down-regulated in infected macaques, whereas TTR,
APOC1 and SERPINA3 were up-regulated.
Conclusions: Some genes involved in oxygen or lipid transport and in innate immunity were found to be dysregulated
in prion infected macaques. These genes are known to be involved in other neurodegenerative disorders such as
Alzheimer’s and Parkinson’s diseases. Our results may facilitate the identification of potential disease biomarkers for
many neurodegenerative diseases.
Keywords: Prion diseases, BSE, Non-human primates, Neurodegeneration, Transcriptome, Microarray, RT-qPCR,
Biomarker, Serpina3, Hemoglobin
Background
Prion diseases, or transmissible spongiform encephalop-
athies (TSEs), are incurable and fatal neurodegenerative
disorders that affect both humans and animals; their origin
may be sporadic, acquired or genetic [1,2]. TSEs include
Creutzfeldt-Jakob Disease (CJD), Gerstmann-Sträussler-
Scheinker syndrome (GSS), kuru and fatal familial insomnia
(FFI) in humans [2], bovine spongiform encephalopathy
(BSE) in cattle [3], scrapie in sheep and goats [4], chronic
wasting disease (CWD) in cervids [5], transmissible mink
encephalopathy, and feline spongiform encephalopathy
(FSE) [6].
A major event that leads to the development of prion
diseases is the conversion of the cellular form of the prion
protein (PrPC) into an abnormally folded, β-sheet enriched
and protease resistant isoform (PrPSc). PrPSc is prone to
accumulate and aggregate in the brain of affected individ-
uals [1,2,4] leading to neuronal loss, spongiosis and astro-
gliosis, which are hallmarks of neurodegeneration. The
underlying conversion mechanism of PrPC into PrPSc is
poorly understood and it is further complicated by the ex-
istence of several different strains characterized by distinct
* Correspondence: legname@sissa.it
†Equal contributors
1Department of Neuroscience, Scuola Internazionale Superiore di Studi
Avanzati (SISSA), Via Bonomea 265, 34136 Trieste, Italy
Full list of author information is available at the end of the article
© 2014 Barbisin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Barbisin et al. BMC Genomics 2014, 15:434
http://www.biomedcentral.com/1471-2164/15/434
tertiary and quaternary structures as well as different clin-
ical patterns [7,8]. Several hypotheses exist about the con-
tribution of unknown molecules other than PrP to prion
propagation [9-11]. To address this issue, several animal
studies have investigated the host response to prion infec-
tion of different origin and strain. The differential tran-
scription profile after prion infection has been extensively
explored (reviewed in [6,12]); however, most of the studies
involved animal models such as mice [13-18], sheep
[4,19-22] and cattle [23-28], all not closely related to
humans. Some expression analyses have been conducted
in non-human primates focusing mainly on the suscepti-
bility to the infection and the variety of clinical symptoms
[29-33], but none has investigated large-scale transcrip-
tome changes due to prion infection. All these investiga-
tions suggest that besides the PrP-encoding gene (PRNP
in humans), other genes are key players and contribute to
the genetic susceptibility to acquired TSEs [6,34]. The
main genes identified so far are related to oxidative stress,
mitochondrial apoptotic pathways, endosome/lysosome
function, immunity, synapse function, metal ion binding,
activated cholesterol biosynthesis, immune and inflamma-
tory response, protease inhibitors, calcium binding pro-
teins, regulation of the actin cytoskeleton, ion transport,
cell adhesion, and transcription processes [6]. Dysregula-
tion of these genes seems to cause increased oxidative
stress that in turn determines oxidation of proteins,
lipids and DNA as well as mitochondrial dysfunction
and ER stress [6]. Apart from TSEs, transcriptional
changes of these genes are common to other neurode-
generative pathologies [12] and, together with func-
tional proteomics data, may help to identify novel
selective biomarkers of prion diseases and neurodegen-
eration in general.
To accomplish that, we performed a large-scale tran-
scriptional profiling in BSE-infected cynomolgus ma-
caques (Macaca fascicularis). They are known to be an
excellent model for studying human acquired prion dis-
eases [32,33,35-37], as shown by BSE transmission via
the intracranial and oral routes, which lead to a disease
pattern comparable to that of human maladies in terms
of preclinical incubation time, clinical symptoms and
pathophysiology [35]. The objective of this study was to
identify genes that are differentially expressed in brain
tissue of intracranially infected monkeys compared to
non-infected ones using an unbiased genomic approach
such as expression microarrays with subsequent data
validation by RT-qPCR. Our study aims at revealing bio-
logical processes that are relevant to the pathogenesis of
human prion diseases using a systematic approach that
connects the identified DEGs into potential networks of
interacting pathways. This may allow us to discover
novel selective markers as potential targets for diagnostic
and therapeutic strategies.
Results
PrPSc content in brain tissue
The relative amount of PrPSc in brain homogenate of 6
BSE-infected macaques was examined by Western Blot.
Densitometric analysis of the monoglycosylated band re-
vealed that the relative amount of PrPSc strongly differed
between the individual macaques. We wondered whether
this discrepancy might be due to the preclinical incubation
time or rather correspond to the gradual accumulation of
PrPSc during the clinical phase of disease as reported for
sCJD [38,39]. As anticipated, we found a significant correl-
ation between PrPSc content and the duration of the
symptomatic phase (Figure 1). The correlation analysis in-
cludes only the 6 intracranially inoculated macaques.
Since these animals were housed in one social group, en-
vironmental factors, which may influence the disease
course and duration, are identical. Such factors can be dif-
ferent for the orally inoculated animal, which was there-
fore omitted from the analysis. The infected animals were
at an advanced stage of prion disease and the details of
their clinical course have been previously described [33].
Briefly, animal A1 showed the shortest duration of disease
(17 days) and a short pre-clinical incubation time
(931 days) together with the lowest PrPSc content, while
animal A5 showed the longest survival period (143 days),
compared to an average clinical phase of about 90 days,
together with the highest PrPSc content and the second
longest pre-clinical phase (1340 days).
Microarray analysis of brain gene expression in
cynomolgus macaques
To investigate differential mRNA expression in BSE-
infected macaques we used brain samples from 6 animals
that were intracranially challenged [33]. One macaque that
Figure 1 Correlation between PrPSc content and duration of
clinical phase. Western Blot analysis from PK-treated homogenates
of brain samples derived from BSE-infected macaques was performed.
The monoglycosylated bands of PrPSc were analyzed densitometrically.
Relative amounts of PrPSc from brain homogenates were averaged and
correlated to the disease duration.
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was orally infected with 50 mg BSE-homogenate was also
included in our study. For comparison purposes, we used
5 brain samples derived from non-infected age- and sex-
matched control macaques.
RNA was isolated from the gyrus frontalis superior of
all animals and checked for quality by nano-scale elec-
trophoresis, which resulted in an overall RNA Integrity
Number (RIN) of about 6. This value is indicative of at
least partially degraded RNA within the sample; one
possible reason for the reduced RNA integrity may be
the procedure utilized to remove the gyrus frontalis su-
perior region from the frozen tissue slide. The biopsy
stamp was plugged into a cordless screwdriver that was
used to drill a borehole in the frozen tissue block of +/−
1 cm height. This method was chosen to ensure that the
material did not thaw; however, the local heat induced
by the rotating biopsy stamp may have led to substantial
degradation of the RNA. Nonetheless, human brain ma-
terial exhibiting a comparable RIN value was successfully
used for similar studies [40]. All samples were analyzed
using the GeneChip® Rhesus Macaque Genome Array
(Affymetrix®) that contains 52,024 rhesus probe sets to
enable gene expression studies of Macaca mulatta tran-
scriptome interrogating more than 47,000 transcripts.
The genomes of M. mulatta and M. fascicularis exhibit
a small genetic divergence of approximately 0.4% [41,42]
that presumably allows for the detection of homologue
transcripts with high specificity.
Raw data were quality checked and analyzed using
Affymetrix® proprietary analysis tools, a hierarchical
clustering was performed and a heat map was generated.
Then the signals were aligned to the annotation library
and a spreadsheet containing gene symbols, p-values
and expression fold changes was created. Microarray
data were submitted to Gene Expression Omnibus (GEO).
The bioinformatics analysis identified 300 probe sets that
were up- or down-regulated about twofold (≥ |1.95|). Be-
cause among them no candidate appeared using FDR
0.05, we chose as criteria an unadjusted p-value of ≤ 0.005
together with a fold change ≥ |2.0|. Additional file 1 lists
the resulting 86 probe sets that were then used to generate
the heat map shown in Figure 2.
Functional classification of differentially expressed genes
(DEGs)
We used the Ingenuity Pathways Analysis (IPA®, see sec-
tion: Availability of supporting data) to annotate genes
according to their functional relationships and to deter-
mine potential regulatory networks and pathways. Among
the 300 differentially expressed (about twofold, (≥ |1.95|)
probe sets identified, 105 were associated to mapped IDs;
53 of the latter were identified as network eligible genes,
while 86 were identified as function eligible genes. It
should be emphasized that the designation of functional
class in the present study is neither definitive nor exclu-
sive, as annotation of gene function is incomplete, and
Figure 2 Condition trees of the clustering analysis. The cluster analysis was performed using a hierarchical approach with the average
linkage-method (R and Partek® Software, Partek® Inc.): 86 probe sets showed a differential expression with FC ≥ 2. The color represents the level of
expression (red: up-regulation, blue: down-regulation) and the sample information is listed across the bottom. The names of the known genes
are indicated. More details on all genes are reported in Additional file 1.
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multifunctional gene products can be involved in several
cellular pathways. First, we identified key biological func-
tions and/or diseases that contain a disproportionately
high number of genes from the DEG list compared to the
total gene population from the microarray. The analysis
was started by identifying the top categories (p < 0.01) of
DEGs within three main classes. In the “Diseases and
Disorders” class the categories were cancer and develop-
mental disorder, while within the “Molecular and Cellular
functions” class most genes were involved in cellular de-
velopment and cell death/survival. The main categories
for the “Physiological System Development and Function”
class were tissue morphology as well as nervous system
development and function. As a second step, genes were
clustered in relation to the main pathways they belong to:
the top two canonical pathways in our DEG list were
LXR/RXR activation, which is associated with lipid metab-
olism and transport, and acute phase response signaling.
Identification of biologically relevant networks
To further investigate the global expression response to
BSE infection and to define interactions among the iden-
tified specific pathways containing the regulated genes,
potential networks of interacting DEGs were identified
using IPA®. All potential networks with score > 9 (a
score ≥ 3 was considered significant, p < 0.001) are listed
in Table 1 with information on network genes, score,
focus molecules and top functions associated with the
focus genes in each network. The highest ranked
network identified by IPA® was associated with tissue
morphology (specifically the determination of cell quan-
tity), developmental disorder and biological processes
controlling cell death and survival (Figure 3a). This net-
work contained genes that are known to be involved in
several neurological diseases and nervous system func-
tions, as shown in Figure 3b.
Validation of differentially expressed genes by RT-qPCR
To further confirm the array results using an independ-
ent and more sensitive technique, we decided to perform
RT-qPCR for a subset of differentially expressed genes.
This subset (Additional file 2) was selected in subse-
quent steps: first, among the 86 probe sets identified
during the microarray analysis (Additional file 1) we se-
lected the top 36 with fold change ≥ |2.5| and p ≤ 0.005.
Then, after realizing that many were not annotated or did
not have a known function, we extended the selection to
additional 29 probe sets having fold change ≥ |2.5| but
0.005 ≤ p ≤ 0.05; for the same reasons stated above, we ex-
tended the list of candidates one more time using as cri-
teria fold change ≥ |2.5| and p > 0.05 (24 candidates). At
this point, having still some cDNA available and only 13
feasible candidate transcripts, we added seven probe sets,
corresponding to 5 additional transcripts, selected among
the ones with a slightly lower fold change (FC ≥ 2 for at
least 1 probe) but possessing an interesting function as re-
vealed by the IPA® analysis or according to the literature.
Lastly, HBA2 was added to the list because of its tight
Table 1 List of 3 Ingenuity networks generated by mapping the focus genes that were differentially expressed between
non-infected and BSE-infected samples
ID Molecules in network Score Focus
molecules
Top functions
1 ACVR1C, AKR1D1, Alp, AMPK, Ap1, APOC1, Calcineurin protein(s), CARTPT, caspase,
CD3, CHI3L1, Creb, cytochrome C, DACH1, DLK1, ERK, ERK1/2, F13A1, Focal adhesion
kinase, GNRH1, HBA1/HBA2, HBB, HDL, hemoglobin, HEY2, HINT1, HIPK2, Ikk (family),
IL1, IRF3, Jnk, KDELR2, LDL, LGALS1, Mapk, MEF2C, Mek, MET, MT2A, N4BP1, NADPH
oxidase, NGFR, NR4A2, OTX2, P38 MAPK, p85 (pik3r), Pdgf (complex), PDGF BB, PI3K
(complex), PI3K (family), PIK3R3, Pkc(s), PLC gamma, PON3, Pro-inflammatory Cytokine,
Ras, SERPINA1, SERPINA3, Shc, SHOC2, SLCO1A2, Sos, STK4, TCF, TCR, TNFSF10, TTR,
TWIST1, Vegf, WSB1
71 35 Tissue Morphology, Cell Death and
Survival, Developmental Disorder
2 ABR, ACTL6B, ARMC6, ASB6, C10orf137, C6orf211, CAMKV, CHMP2A, CLIC4, CLPP,
CSNK1G3, CTBP2, DCLRE1A, DDX19B, DGKE, ECT2, FHL3, FLVCR1, GALNTL5, GLOD4,
HEATR6, HSP90AA1, HSPA12A, ITFG1, KLF3, KPNA6, MCTS1, MEIG1, METTL7B, MRPL44,
MXD3, MYBPC1, NCLN, NIPBL, NOL4, OSBPL10, PCBP3, PLEKHA8, PMM2, POLR2J,
PPAP2C, PRCP, PROSC, RAI2, SAP18, SCAND1, SEPT6, SGTB, SMARCC1, SMC3,
SPATA22, SPSB3, SRPK3, SSU72, STAG1, TATDN1, TESPA1, TM7SF3, TNK1, TNNI3K,
TP53BP1, TRAPPC2L, TRIP12, TUFM, TXNL4A, UBC, ZNF131, ZNF235, ZNF397, ZNF420
54 28 Developmental Disorder, Hereditary
Disorder, Hematological Disease
3 26 s Proteasome, ADCY, AKR1C1/AKR1C2, Akt, APP, ARL4C, Arntl-Clock, AVP, AVPR1B,
CACNA1B, CAMKV, CARTPT, CBLN2, CEACAM6, CLDN10, CLOCK, COX4I2, CTF1,
DNAJC12, endocannabinoid, estrogen receptor, FAM46A, FSH, GABRE, GNA15,
GPR158, GPX1, GPX2, GSK3A, Histone h3, HMGCR, HNF4A, HSPA12A, Insulin, JPH3,
KCNC3, KCNS1, LINGO1, LPAR1, LXN, MGAT2, miR-125b-5p (and other miRNAs w/seed
CCCUGAG), Mmp, MST1, NFkB (complex), Npff, OPN1LW, PDX1, PIK3R5, Pka, PKM,
PLC, Proinsulin, RAB39A, RAI2, RIOK2, RUFY3, SERPINA3, SMAD5, SMC4, SOX7, SYT17,
TCF19, Tnfrsf22/Tnfrsf23, TOR2A, tretinoin, trypsin, TXNL4B, ZBTB44, ZFHX3
36 21 Cellular Development, Neurological
Disease, Skeletal and Muscular System
Development and Function
Names in lowercase are genes/molecules that are not from the DEG list but are associated with some of them within pathways identified by Ingenuity Pathway
Knowledge Base (IPKB).
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relationship with one of the previously selected genes of
the hemoglobin complex (HBB), as revealed in the top
ranking network from the IPA® analysis (Figure 3a). In
summary, we designed RT-qPCR assays for 19 genes
(Table 2) and most of them were already known to be in-
volved in neurodegenerative disorders or nervous system
regulation, even though very few had been implicated in
prion diseases. Among these, we were able to successfully
analyze only 11 (reported in Table 3 together with 2
housekeeping genes, ACTB and GAPDH), since the RT-
qPCR assays for the remaining 8 genes either showed too
low expression (CT > 35) or amplification of trace
amounts of residual gDNA. Furthermore, because several
gene names have changed since the first annotation was
done, updated names from the latest Affymetrix® anno-
tated library are provided in Additional file 2, together
with the old ones.
In order to achieve optimal RT-qPCR conditions we
performed titration of template and primers as well as
optimization of cycling conditions using human cDNA
from SH-SY5Y neuroblastoma cells (macaque cDNA
was scarce). To assess the specificity of the chosen oligo-
nucleotides prior to performing the quantitative assays,
some reactions were carried out using macaque cDNA
obtained from control animals to verify the correct
amplicon length. Two housekeeping genes, GAPDH and
ACTB [61], were used as reference genes to normalize
RT-qPCR data. Both genes were monitored across sam-
ples derived from infected and control macaques in
order to evaluate their expression stability, yielding very
similar results (Additional file 3).
At this point we performed the quantitative analysis and
in general we observed large intra-assay variability for
most genes across different samples, both for infected
(See figure on previous page.)
Figure 3 Identification of biologically relevant networks. (a) Top ranking network generated by mapping the focus genes that were
differentially expressed in infected animals. Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB) is shown. Color shading
corresponds to the type of dysregulation: red for up-regulated and green for down-regulated genes according to the microarray fold change
calculation method. White open nodes are not from the list of 300 DEGs, but are transcription factors that are associated with the regulation
of some of these genes identified by IPKB. The shape of the node indicates the major function of the protein. A line denotes binding of the
products of the two genes, while a line with an arrow denotes 'acts on'. A dotted line denotes an indirect interaction. (b) Schematic representation
of nervous system-related functions for selected DEGs. The most regulated/interesting DEGs were selected and associated to known nervous system-
related functions according to the Ingenuity Pathway Knowledge Base (IPKB) software.
Table 2 Candidate genes for validation
Gene Accession number Known relation with PrP/nervous system References
AKR1C1 NM_001195574.1 Putative role in myelin formation [43]
HBB NM_001164428.1 Putative role in intraneuronal oxygen homeostasis, reduced in Alzheimer's and Parkinson's disease [44]
NCAM1 XM_001083697.2 PrP/N-CAM complexes found in prion infected N2a cells [45]
NR4A2 NM_001266910.2 Mutations related to dopaminergic dysfunction, including Parkinson schizophrenia and depression [46,47]
USP16 NM_001260999.2 Depletion of USP16 prevented ATMi from restoring transcription after DSB induction [48]
CALB1 XM_001085269.2 Plays a protective role in neurodegenerative disorders (depleted in HD) [49]
DACH1 XM_001082371.2 Required for normal brain development [50]
LXN NM_001266988.1 Marker for the regional specification of the neocortex [51]
PIK3R3 NM_001266826.1 Linked to β-amyloid plaque formation in AD brain [52]
SAP18 NM_001261034.1 Possibly related to AD [53]
SERPINA3 NM_001195350.1 Increased in schizophrenia, SNPs affecting onset and duration of AD [54,55]
TNFSF10 NM_001266034.1 Implicated in pathogenesis of MS (causing demyelination) [56]
HBA2 NM_001044724.1 Putative role in intraneuronal oxygen homeostasis, reduced in Alzheimer's and Parkinson's diseases [44]
GNRH1 NM_001195436.1 Key regulator of the reproductive neuroendocrine system in vertebrates [57]
IRF3 NM_001135797 Putative protective role against prion infection [58]
APOC1* AK240617.1 Binds to ApoE, risk factor for Alzheimer's disease [59]
TM7SF3 XM_001099269.2 - -
MYBPC1 XM_001091952.1 - -
TTR NM_001261679 Amyloid neuropathies, interaction with Aβ [60]
List of 19 identified genes selected on the basis of fold change value and known relevance for neurodegeneration. Because of very low signal (LXN, PIK3R3,
TNFSF10, GNRH1) or lack of reliable sequence data (CALB1, DACH1, TM7SF3, MYBPC1), only 11 genes (in bold) were successfully analyzed. *Macaca fascicularis transcript.
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(Additional file 4) and for control animals (Additional file 5).
Interestingly, we found a completely different expression
pattern for B6, the only orally-infected sample, compared
to the intracranially infected animals, except for a couple
of genes (AKR1C1, NCAM1), suggesting that the route
of infection might play a role in determining the gene
expression changes (Additional file 6). Therefore we de-
cided to rerun the microarray clustering analysis exclud-
ing this animal in order to verify its influence on the
final results. As shown in Additional file 7, the compari-
son of the clustering analysis with (panel A) and without
(panel B) the orally challenged animal B6 does not show
marked differences.
Using SYBR® Green-based RT-qPCR we confirmed
the statistically significant up-regulation of TTR (FC =
7.11), SERPINA3 (FC = 18.73) and APOC1 (FC = 6.33)
as well as the down-regulation of HBB (FC = 0.19) and
HBA2 (FC = 0.22), normalizing the data against GAPDH
(Figure 4). Similar results were obtained against ACTB
(Additional file 8). For all the other genes the RT-qPCR
results confirmed the regulation trend of the microarrays,
but without statistical significance (p-value > 0.05).
In order to confirm the SYBR® Green -based results
we performed an additional RT-qPCR analysis using
FAM-labeled TaqMan® probes, providing more sensitive
and specific detection signals for those genes that
showed a significant fold change. Using this approach
we confirmed the regulation of SERPINA3, APOC1,
HBB and HBA2, but not of TTR, which showed com-
parable trends in FC but lost statistical significance
(Figure 5). This may be due to higher variability among
triplicates, caused by CT values higher than 35 obtained
with the TaqMan® probe chemistry compared to SYBR®
Green detection system (Additional file 9).
Table 3 Genes analyzed by RT-qPCR
Gene Chromosome Primer sequence Amplicon length (bp) Accession number
ACTB 3 F: GTTGCGTTACACCCTTTCTTG 146 NM_001033084.1
R: CTGTCACCTTCACCGTTCC
GAPDH 11 F: CCTGCACCACCAACTGCTTA 74 NM_001195426.1
R: CATGAGTCCTTCCACGATACCA
AKR1C1 9 F: CCGCCATATTGATTCTGCTCAT 132 NM_001195574.1
R: TGGGAATTGCACCAAAGCTT
HBB 14 F: GTCCTCTCCTGATGCTGTTATG 102 NM_001164428.1
R: TTGAGGTTGTCCAGGTGATTC
NCAM1 14 F: GAGCAAGAGGAAGATGACGAG 150 XM_001083697.2
R: GACTTTGAGGTGGATGGTCG
NR4A2 12 F: CCAGTGGAGGGTAAACTCATC 145 NM_001266910.2
R: AGGAGAAGGCAGAAATGTCG
USP16 3 F: GCAGAACTTGTCACAAACACC 146 NM_001260999.2
R: CTAAAGTAAGAGGGCCTGGAG
SAP18 17 F: GGAAATGTACCGTCCAGCGA 109 NM_001261034.1
R: TGCCCTTCTTTCTAGCTTCTGG
SERPINA3 7 F: GCTGGGCATTGAGGAAGTCT 123 NM_001195350.1
R: GTGCCCTCCTCAGACACATC
HBA2 20 F: CGACAAGAGCAACGTCAAGG 126 NM_001044724.1
R: TCGAAGTGGGGGAAGTAGGT
IRF3 19 F: TGGGTTGTGTTTAGCAGAGG 90 NM_001135797
R: GAAAAGTCCCCAACTCCTGAG
APOC1* 19 F: TTCTGTCGATGGTCTTGGAAG 138 AK240617.1
R: CACTCTGTTTGATGCGGTTG
TTR 18 F: TCACTTGGCATCTCCCCATTC 114 NM_001261679
R: GGTGGAATAGGAGTAGGGGCT
Primers (F: forward and R: reverse) used for gene amplification, amplicon length and GenBank® accession numbers of the macaque cDNA sequences used for
primer design. All primers were designed according to the genome sequence of Macaca mulatta.
*Apolipoprotein C-I (APOC1) primers were designed according to the genome sequence of Macaca fascicularis because the Macaca mulatta mRNA sequence was
not annotated (TSA Macaca mulatta Mamu_450725, accession number: JV045807.1). Homology between the two sequences was 99%.
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Figure 4 SYBR® Green-based RT-qPCR validation of microarray results. Relative expression levels of 11 genes normalized against GAPDH in
BSE-infected cynomolgus macaques.
Figure 5 Comparison between SYBR® Green-based and TaqMan® probe-based results. TaqMan® (white) versus SYBR® Green-based (grey)
expression levels for each transcript. Both detection systems yielded similar results. Data are normalized against GAPDH. Similar results were
obtained with normalization against ACTB (data not shown).
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In general, we were able to confirm the results of
the array platform obtaining consistent fold change
values for all genes analyzed, even though we validated
with statistical significance using the specific TaqMan®
detection system only four of them: HBB, HBA2,
APOC1, SERPINA3 (see Table 4 for details on p-values
and FC).
In addition, dealing with animals whose brain mate-
rial isolation may be susceptible to blood contami-
nation, and as several works in the last few years have
shown the presence of active transcription within hu-
man red blood cells [62], we decided to analyze the
samples also for expression of some erythrocyte
markers, such as ALAS2 and RHAG, in order to verify
the reliability of the results related to the regulation of
both chains of hemoglobin (HBB and HBA2). Al-
though the array data for these genes suggested a neg-
ligible and virtually identical presence of blood in both
control and infected samples, RT-qPCR analysis revealed
a small blood contamination (CT ≥ 34 for ALAS2, CT ≥
36 for RHAG) within two samples, one control (CovD1)
and one infected sample (A4) (Additional file 10 and
Additional file 11). In light of these results, we performed
an additional gene expression analysis for HBB and
HBA2 excluding these two samples. As expected, we
obtained slightly different results (FC ~ 0.3 for HBB
and 0.2 for HBA2 using TaqMan® probes), but a rele-
vant down-regulation still persisted with statistical
significance.
Discussion
The precise mechanisms regulating the molecular pro-
cesses that lead to neurodegeneration in TSEs remain
unknown. Genomic approaches represent unbiased and
powerful tools to uncover the molecular basis of these
complex mechanisms and they may also contribute to
discover new biomarkers for these diseases. Several stud-
ies have presented genomic analyses of brain tissues
from animal models of TSE; a few of them involved the
mRNA profiling of cattle BSE [23,25-27] or ovine scrapie
[4,19-22,63] whereas the vast majority was performed on
rodent-adapted models of prion disease [13-18,64]. In
several of these prion-infected mice, genomic expression
profiles revealed the induction of oxidative and endoplas-
mic reticulum (ER) stress, activated ER and mitochondrial
apoptosis pathways as well as activated cholesterol biosyn-
thesis in the CNS of preclinical mice [64].
We report here the first large-scale transcriptome
analysis of the superior frontal gyrus of BSE-infected
macaques. This region was selected based on its histo-
pathological and functional relevance in the majority of
neurodegenerative disorders [65] and because it corre-
sponds to Brodmann areas 10 and 11, known to be in-
volved in strategic processes in memory recall, various
executive functions as well as in planning, reasoning,
and decision making [66], all processes known to be dis-
turbed by neurodegeneration. In general, RT-qPCR re-
sults confirmed the regulation trend seen in the
microarray platform for all the 11 genes analyzed with
very similar values using either GAPDH or ACTB for
normalization. For five of them (HBB, HBA2, TTR, SER-
PINA3, APOC1) we obtained statistical significance with
one or both qPCR detection systems utilized in this
study (SYBR® Green and TaqMan® probes) and some of
them were involved in the top two canonical pathways
identified during the functional classification reported in
the Results section: APOC1 and TTR are part of the
LXR/RXR activation pathway, which is associated with
lipid metabolism and transport, whereas SERPINA3 and
TTR are involved in the acute phase response signaling
pathway. All the other genes seemed to fall in the grey
zone of both platforms and therefore their FC values
could not be considered reliable.
When validating the array results by RT-qPCR, the
first evidence obtained was a marked variability among
the samples of the same group, either control or infected
animals. Unlike other animal models, nonhuman pri-
mates are usually not inbred. Therefore, differences in
the genomic background of the animals in our study
may have contributed to the variability in the time of
disease onset [33] and in gene expression within the
same group. Paradoxically, for some genes that resulted
strongly regulated (APOC1, HBB, HBA2) the variability
resulted even more accentuated within the control group
Table 4 RT-qPCR confirmation of microarray results
Gene symbol Microarray fold change RT-qPCR fold change
SYBR® Green TaqMan®
Min Max Mean FC P value FC P value
AKR1C1 2.3 2.9 2.5 1.7 0.433 2.4 0.235
HBB −2.2 −2.6 −2.4 0.2 0.020 0.3 0.021
NCAM1 −1.1 2.5 −0.3 0.5 0.160 - -
NR4A2 1.1 −2.1 −1.6 0.4 0.248 - -
USP16 −1.2 −5.5 −2.6 0.5 0.308 - -
SAP18 −1.2 −2.6 −1.7 0.8 0.393 - -
SERPINA3 10.0 16.0 13.0 18.7 0.0001 15.3 0.0005
HBA2 - - - 0.2 0.041 0.2 0.019
IRF3 2.0 2.1 2.0 1.3 0.123 - -
APOC1 4.3 - 4.3 6.3 0.047 6.8* 0.028*
TTR 3.1 - 3.1 7.1 0.025 5.9 0.076
Differential expression of selected genes analyzed by microarray and RT-qPCR.
For microarray analysis, the lowest (Min), the highest (Max) and the average
(Mean) fold change values of all the respective probes are shown. For RT-qPCR
analysis, fold change (FC) and statistical significance (p-value) for both SYBR®
Green and TaqMan® results are shown. In bold are the genes validated with
statistical significance. HBA2 was not present in the array chip.
*Normalization performed vs. ACTB only.
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if compared to that of the infected group. The experi-
mental and control animals were housed in different
animal facilities and this may have generated slight dif-
ferences in diet and/or housing conditions that may have
contributed to the above-mentioned effect.
We also reported a peculiar dysregulation pattern of
the orally infected sample (B6) for several genes, show-
ing a completely opposite trend compared to intracrani-
ally infected animals. Although no data are available for
PrPSc deposition in brain or other tissues of this animal,
the significantly longer incubation period (1950 days
compared to an average of 1100 days for the other ani-
mals) could suggest a correlation between the mRNA
expression profile and the route of infection [67]. None-
theless, this different pattern may be due to the age dif-
ference at the time of euthanasia: 7.1 +/− 0.7 years for
the intracranially infected macaques versus 9.9 years for
the orally infected animal.
Concerning hemoglobin (Hb), a few years ago its ex-
pression was unexpectedly discovered in mesencephalic
dopaminergic neurons of different mouse strains, as well
as in rats and humans affected by Parkinson's disease
(PD) and multiple sclerosis (MS) [68-70].
Hb expression is known to decrease in neurons of PD,
Alzheimer’s disease (AD), argyrophilic grain disease
(AGD) and dementia with Lewy bodies (DLB) brains
[44] as well as in the CNS of scrapie-infected mice
[13,14]. Also, it has been shown that Hb binds to Aβ en-
hancing its aggregation and co-localizes in amyloid pla-
ques in AD brains [71]. If we consider a possible similar
interaction with β-rich PrPSc isoforms in prion diseases,
we can hypothesize that in our animal model down-
regulated Hb fails to promote aggregation of the prion
protein, thus leading to a higher presence of toxic spe-
cies like oligomers [72]. Moreover, in PD it has been hy-
pothesized that Hb may act as oxygen storage molecule
in oligodendrocytes [68]. Oxygen would be later released
to neighboring neurons in hypoxia conditions to main-
tain the aerobic metabolism [68,69]. When down-
regulated, Hb would not be available for this function and
cells would be damaged by the defective oxygen homeo-
stasis. Our results indicated a strong down-regulation
(about 70-80% lower expression than normal) of both
HBB and HBA2 in symptomatic advanced-stage BSE-
infected macaques. The data were analyzed with a very
stringent procedure after excluding any major effect of po-
tential blood contamination, thus confirming the robust-
ness of the results.
Taken together, all these data indicate a possible gen-
eral role for hemoglobin in neurodegenerative disorders,
possibly related to an alteration of O2 homeostasis and
oxidative metabolism [68]. One point that needs further
investigation is whether this alteration (down-regulation)
occurs as an early/late consequence of the disease, or
may act as a susceptibility factor that influences the onset
of the pathology. Furthermore, future studies may investi-
gate the localization of the observed down-regulation in
terms of cell population: it could involve neurons as well
as astrocytes or microglia.
Another crucial molecule, APOC1, was significantly
up-regulated in BSE-infected brains samples compared
to controls. Apolipoprotein C-I, whose gene APOC1 is
part of the APOE/C-I/C-IV/C-II gene cluster, (apoC-I) is
a small 6.6 kDa component of lipoproteins (mainly
HDL) that is known to inhibit receptor-mediated lipo-
protein clearance, especially particles containing apoE
[73]. Increasing evidence indicates a role for this gene in
neurodegenerative disorders, especially in AD and MS
[74-76]. A disruption in lipid metabolism and signaling
is one of the early alterations apparent in many neurode-
generative diseases, including prion diseases [77,78]; in-
deed, cholesterol metabolites are investigated by a
number of studies aimed at the identification of early
biomarkers for neurodegenerative disorders [79-81]. Sev-
eral genes involved in cholesterol metabolism and lipid
biosynthesis have been found to be up-regulated in
preclinical scrapie-infected mice [64]. Since APOC1 is
able to activate cholesterol esterification via lecithin-
cholesterol acyltransferase [75], its up-regulation could
lead to an increase in cholesterol biosynthesis, consistent
with the concomitant presence of prion disease. In fact,
in vitro studies have shown that depletion of cellular
cholesterol reduces the conversion of PrPC to PrPSc [82]
and evidence exists also in AD, where altered cholesterol
metabolism has been found [83]. Hypercholesterolemia
has also been shown to influence amyloid precursor pro-
tein processing [84]. One explanation for altered choles-
terol homeostasis affecting prion disease development
could lie in the fact that PrP is localized in cholesterol-
rich lipid rafts [85].
SERPINA3, a serpin peptidase inhibitor involved in
acute phase response pathways, is another gene that we
found highly regulated in our animal model. It is exten-
sively reported to be regulated in other neurodegenera-
tive disease models and in particular it is well known to
interact with APP to promote amyloid plaque formation —
a hallmark of AD [86]. Indeed, increased levels of
SERPINA3 have been found in the brain and peri-
pheral blood of AD patients [87], mainly due to per-
sistent and almost chronic inflammation [88]. In prion
disease studies, SERPINA3 was found increased in brains
of scrapie-infected mice [77], in mice infected with RML
prior to clinical onset [89] as well as in urine and cerebro-
spinal fluid of CJD patients [90]. Being an acute phase
protein, its up-regulation is explained by the onset of an
inflammatory condition, particularly as a response of the
innate immune system [91]. Interestingly, two β-sheets of
SERPINA3 exhibit a polymorphism mimicking changes in
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the serpin structure that normally occur during the forma-
tion of its stable complex with the target proteinase. In
this conformation, SERPINA3 can bind Aβ, thus imposing
a β-strand conformation that upon dissociation leads to a
faster formation of fibrils [86]. Therefore, an intriguing hy-
pothesis may be envisioned in which PrP conversion into
β-sheet conformation can be assisted by SERPINA3,
which would accelerate the formation of toxic species like
PrP oligomers.
Transthyretin, a protein in the same pathway of acute
phase response as SERPINA3, was found to be up-
regulated at the transcription level in our BSE-infected
macaques according to the SYBR® Green assay. Even
though we were not able to confirm the statistical sig-
nificance using the TaqMan® assay, this gene seems to be
of interest. Indeed, TTR, carrier of the thyroid hormone
thyroxine (T4) in serum and CSF, is associated with
systemic amyloidosis in humans [92], but also with an
anti-amyloidogenic effect preventing Aβ deposition in
neuronal cell cultures [93]. Moreover, increased mRNA
and protein levels have been shown in neurons from the
AD mouse model ‘APP23’ and in human AD brain with
a neuroprotective role [94,95]. Even in prion models
TTR levels have been found strongly increased in the
cortex of scrapie-infected mice [15]. Our study now pro-
vides indication that up-regulation of TTR may also be
found in BSE-infected macaques, further reinforcing the
hypothesis of a common mechanism in AD and TSEs.
Taken together, these data may suggest innate immune
system activation and inflammatory response in these
diseases [96], leading to a sustained up-regulation of
both SERPINA3 and TTR genes simultaneously: SER-
PINA3 as inflammation effect, TTR as attempt to
neutralize the infectious agent preventing its deposition.
However, analysis of the microarray data did not reveal
relevant deregulation of other genes typically involved in
neuroinflammation and/or immune response, such as
cytokines and other mediators. Even though some au-
thors have reported alteration of these pathways [97], in
our array IL6, TNFα, GFAP and CD68 showed a fold
change < |2|, suggesting that inflammatory responses
may not be particularly severe in this model.
One last point that remains to be addressed is the ex-
pression of the prion protein gene itself (PRNP in
humans) upon infection. Because of shortage of cDNA,
we were not able to validate its levels in our samples.
Nevertheless, our microarray data did not identify any
changes between control and infected samples, at least
at the mRNA level. This is in agreement with findings
reported for BSE-infected cattle [3], but differs from the
situation in sporadic CJD patients who show reduced
mRNA expression [97]. Whether this disagreement is
related to the host or the infectious agent needs to be
explored.
Conclusions
To our knowledge, this is the first genome-wide expres-
sion study in the gyrus frontalis superior region of cyno-
molgus macaques inoculated with BSE. Using microarray
and RT-qPCR technologies we identified a gene signature
able to distinguish infected macaques from control ani-
mals. These results could be extremely helpful in under-
standing the progression of the disease, allowing for the
identification of some key players which, if not being the
cause of the onset, could be some of the target genes af-
fected by the disease. Therefore, after deeper investiga-
tions to validate these targets at the protein level and
confirm their specificity for prion diseases, they may be
exploited as potential biomarkers to set up pre-clinical
diagnostic tests.
In particular, our findings support the hypothesis of a
potential shared mechanism underlying the onset and
the development of all neurodegenerative disorders, as
the majority of our DEGs are known to be involved in
other diseases such as AD or PD. This is in concordance
with very recent data supporting the idea of a unifying
role of prions in these diseases in general and maybe a
prion-like behavior for most neurodegenerative disorders
[98]. Furthermore, some of the DEG transcripts we found
are present also in blood (hemoglobin, transthyretin, ser-
pin peptidase inhibitor) and among them hemoglobin ex-
hibited decreased expression throughout the entire course
of the infection, including preclinical time points, in
mouse models. Therefore, there is the intriguing possibil-
ity to employ these "readily available" biomarkers for diag-
nostic purposes, especially if additional studies will
confirm the expression level of the proteins encoded by
these DEGs in brain and/or blood tissue.
In general, our results suggest that, in order to identify
potential biomarkers and drug targets for prion diseases
and other neurodegenerative disorders, a combination of
various pathways has to be targeted, including oxygen
homeostasis, lipid metabolism and inflammation response.
In summary, large-scale transcriptome analyses of hu-
man TSEs are rare [97,99] and primate models are a
valid approach to better understand the mechanisms of
these fatal diseases. Even with all the limitations dis-
cussed above, our BSE-infected macaques are, to our
knowledge, the closest available model for human vCJD
and these results, obtained with an unbiased metho-
dology as the gene expression microarray technology,
are contributing to shed some light on the molecular
basis of TSEs as well as neurodegeneration as a whole.
Methods
Ethics statement
Ethics approval for the study was issued by the Lower
Saxony Ministry for consumer protection and food
safety (509.42502/08/07.98). Animal experimentation
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was performed in accordance with section 8 of the German
Animal Protection Law in compliance with EC Directive
86/609.
Samples
Samples were derived from six BSE-infected macaques,
Macaca fascicularis (A1 to A6) that were intracranially
inoculated with a single dose of 50 mg brain homoge-
nate (10% wt/vol) [33,37]. One cynomolgus macaque
(B6) was orally inoculated with the same material; inocu-
lation was performed per os, as single dose.
Brain material from five age- and sex-matched non-
infected cynomolgus macaques (CovA, CovB, CovC, CovD1,
CovD2) was obtained from Covance Laboratory Münster
GmbH and processed in an equivalent manner.
Tissue and RNA extraction
At autopsy of seven BSE-infected cynomolgus macaques at
advanced stage of disease and five non-infected control ani-
mals, one hemisphere of the brain was sliced dorso-ventrally
and snap-frozen on dry-ice plates. The gyrus frontalis superior
region was macroscopically identified on the frozen tissue and
removed via a biopsy stamp. Total RNA (RNA>200 bases)
was isolated by manually homogenizing the material with
micro pestles (Kisker Biotech GmbH) in TRIzol (Invitro-
gen). RNA isolation was performed according to the sup-
plier’s instructions. Following RNA isolation, a DNase I
digestion was performed using 1 unit of enzyme per μg
RNA (Fermentas) for 30 min at 37°C, and heat inactivated
for 5 min at 95°C followed by precipitation with Sodium
Acetate/Ethanol. RNA was checked for quantity and purity
on a Spectrophotometer 2000 (PEQLAB) and for integrity of
the 18S and 28S ribosomal bands by capillary electro-
phoresis using the 2100 Bioanalyzer (Agilent Technologies).
Immunoblot analysis
PK-treated (50 μg/mL for 1 hour at 37°C) and untreated
brain homogenates corresponding to 0.7 mg or 0.3 mg
brain tissue, respectively, were separated on 12% Bis/Tris
Acrylamide gels (NuPAGE, Invitrogen) and transferred
to nitrocellulose membranes (Protran, Schleicher &
Schüll, Germany). Detection of macaque PrPSc was per-
formed using the monoclonal anti-PrP antibody 11C6
and a Peroxidase conjugated anti-mouse IgG-antibody
(Sigma-Aldrich, Germany). Signal was visualized using a
chemiluminescent substrate (Super Signal West Pico,
Pierce) and high sensitivity films (Amersham). Densito-
metric analysis of PrPSc was performed using the Image
J program 1.37v.
Microarray analysis using the GeneChip® Rhesus Macaque
genome array
Samples were labeled using the GeneChip® 3’IVT Ex-
press Kit (Affymetrix®). Reverse transcription of RNA
was performed using 500 ng of total RNA to synthesize
first-strand cDNA. This cDNA was then converted into
a double-stranded DNA template for transcription. In
vitro transcription included a linear RNA amplification
(aRNA) and the incorporation of a biotin-conjugated
nucleotide. The aRNA was then purified to remove un-
incorporated NTPs, salts, enzymes, and inorganic phos-
phate. The labeled aRNA of each animal was fragmented
(50–100 bp) and hybridized to a GeneChip® Rhesus Ma-
caque Genome Array (Cat N° 900656; Affymetrix®). The
degree of fragmentation and the length distribution of
the aRNA were checked by capillary electrophoresis using
the Agilent 2100 Bioanalyzer (Agilent Technologies).
The hybridization was performed for 16 h at 1 × g
and 45°C in the GeneChip® Hybridization Oven 640
(Affymetrix®). Washing and staining of the arrays were
performed on the Gene Chip® Fluidics Station 450
(Affymetrix®) according to the manufacturer's recommen-
dations. The antibody signal amplification and washing
and staining protocol were used to stain the arrays with
streptavidin R-phycoerythrin (SAPE; Invitrogen). To amp-
lify staining, SAPE solution was added twice with a bio-
tinylated anti-streptavidin antibody (Vector Laboratories,
Burlingame, CA, USA) staining step in-between. Arrays
were scanned using the GeneChip® Scanner 3000 7G
(Affymetrix®).
Microarray data analysis
Intensity data from the CEL. files were imported to the
Partek® software including a quality control based on in-
ternal controls. All chips passed the quality control and
were analyzed using the Limma package [100] of Bio-
conductor [101,102] and the Partek® software. The
microarray data discussed in this paper were generated
conforming to the MIAME guidelines and are deposited
in the NCBI’s Gene Expression Omnibus (GEO) data-
base [103]. They are accessible through GEO series ac-
cession number GSE52436 (see section: Availability of
supporting data).
The microarray data analysis consisted of the following
steps: 1. quantile method normalization, 2. global clus-
tering and PCA-analysis, 3. fitting the data to a linear
model, 4. detection of differential gene expression and 5.
over-representation analysis of differentially expressed
genes. Quantile-normalization was applied to the log2-
transformed intensity values as a method for between-
array normalization to ensure that the intensities had
similar distributions across arrays.
For cluster analysis, we used a hierarchical approach
with the average linkage-method. Distances were mea-
sured as 1 - Pearson's Correlation Coefficient. The PCA
was performed using the princomp-function in the
Partek® software. To estimate the average group values
for each gene and assess differential gene expression, a
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simple linear model was fitted to the data, and group-
value averages and standard deviations for each gene
were obtained. To find genes with significant expression
changes between groups, empirical Bayes statistics were
applied to the data by moderating the standard errors of
the estimated values [100].
P-values were obtained from the moderated t-statistic
and corrected for multiple testing with the Benjamini–
Hochberg method [104]. The p-value adjustment guaran-
tees a smaller number of false positive findings by control-
ling the false discovery rate (FDR). For each gene, the null
hypothesis, that there is no differential expression between
degradation levels, was rejected when its FDR was lower
than 0.05. Because no candidates appeared using FDR
0.05, we made the selection using another p-value
(unadjusted p-value ≤ 0.005) and a fold change ≥ |2|.
Reverse transcription and RT-qPCR
Validation by quantitative reverse transcription real-time
PCR (RT-qPCR) was performed using gene-specific pri-
mer pairs. cDNA synthesis was accomplished using
100 ng RNA, 10 ng random hexamer primer, 2 mM
dNTPs, 0.5 U RNase inhibitor and 5 U reverse tran-
scriptase (Bioline) in 1× reaction buffer. For each sample
a negative control was carried along by omission of the
reverse transcriptase (−RT control).
The cDNA was diluted 1:10 prior to RT-qPCR. Ten ng
RNA equivalent was added to the reaction mix including
2× iQ™ SYBR® Green Supermix (Bio-Rad Laboratories,
Inc.), 400 nM of the corresponding forward and reverse
primer (Sigma), and quantified in technical triplicates on
an iQ5 Multicolor Real-Time PCR Detection System
(Bio-Rad Laboratories, Inc.). All primers used for RT-
qPCR are listed in Table 3.
After initial denaturation for 3 min at 95°C, 45 cy-
cles were performed at 95°C for 15 sec and 58°C for
1 min. Differential gene expression of candidates was
normalized to GAPDH and ACTB expression. –RT
controls were included in the plates for each primer
pair and sample. The relative expression ratio was
calculated using the ΔΔCT method [105,106]. Signifi-
cance was calculated with the unpaired student t-test
(p < 0.05). Melting curve analysis and gel electrophor-
esis of amplification products were performed for
each primer pair to verify that artificial products or
primer dimers were not responsible for the signals
obtained. Some results were further confirmed using
TaqMan® MGB probes and iQ™ Multiplex Powermix
(Bio-Rad Laboratories, Inc.). The primer sequences,
the reaction setup and the cycling conditions were
the same as described above.
The probe sequences used for the detection of specific
targets were:
GAPDH: 5’-FAM CTGGCCAAGGTCATCCATGA-3’;
ACTB: 5’-FAM-ACAAGATGAGATTGGCATGGC-3’;
HBB: 5’-FAM-AAGTGCTTGGTGCCTTTAGTGATGG-3’;
HBA2: 5’-FAM-TGGCGAGTATGGTGCGGAGG-3’;
SERPINA3: 5’-FAM-TTCCTGGCCCCTGTGATCCC-3’;
TTR: 5’-FAM-ATCGTTGGCTGTGAATACCACCTCTG-3’;
APOC1: 5’-FAM-TGGAGGACAAGGCTTGGGAAGTG-3’.
Availability of supporting data
The microarray data set supporting the results of this
article is available in the Gene Expression Omnibus
(GEO) repository, [http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=wnmjowqqhrcpzod&acc=GSE52436].
The DEGs were analyzed for their functions, pathways
and networks using Ingenuity Pathways Analysis-IPA®
[http://www.ingenuity.com/products/ipa/try-ipa-for-free].
Additional files
Additional file 1: List of 86 differentially expressed probe sets with
p values ≤ 0.005 and FC ≥ │2│. Probe ID, Gene Symbol, Gene Name and
RefSeq Transcript IDs annotation as of release 29 of the Affymetrix®
Rhesus Annotation library (01/July/09). P-values and fold changes are
reported for all 86 probe sets.
Additional file 2: List of 97 differentially expressed probe sets
selected as RT-qPCR candidates. Probe IDs and Previous Gene Symbol
annotation as of release 29 of the Affymetrix® Rhesus Annotation library
(01/July/09). Current Gene Symbol annotation as of the latest Affymetrix®
Rhesus Annotation library (release 32 - 09/June/11). Gene Name and
RefSeq Transcript IDs as of Ensembl release 72 (June 2013). Annotation
using alignment with the human genome has been performed (as stated
in the gene name column) for the most highly regulated probe sets with
unknown macaque annotation. P-values and fold changes are reported
for all genes.
Additional file 3: Evaluation of reference gene expression stability
across non-infected and BSE-infected samples. For each sample,
average values of absolute CTs (+/−SD) of triplicate wells for GAPDH
(grey) and ACTB (white) are shown.
Additional file 4: ΔCT values for all genes showing variability
among BSE-infected samples. ΔCT values (+/−SD) normalized against
GAPDH. Very similar results were obtained with normalization against
ACTB (data not shown).
Additional file 5: ΔCT values for all genes showing variability
among non-infected samples. ΔCT values (+/−SD) normalized against
GAPDH. Very similar results were obtained with normalization against
ACTB (data not shown).
Additional file 6: ΔΔCT values of selected genes in the infected
samples. ΔΔCT values (+/−SD) for HBB, NR4A2, NCAM1, USP16 and
AKR1C1 normalized against GAPDH in the orally-infected animal B6 (white)
compared to intracranially infected samples A1-A6 (grey). Only 5 genes were
analyzed for animal B6 due to shortage of cDNA.
Additional file 7: Cluster analysis. Cluster analysis was performed using
a hierarchical approach with the average linkage-method for all animals
(panel A) or excluding the orally infected one, B6 (panel B).
Additional file 8: SYBR® Green-based RT-qPCR validation of microarray
results. Relative expression levels of 11 genes in BSE-infected cynomolgus
macaques normalized against ACTB as reference gene.
Additional file 9: Comparison between SYBR® Green -based and
TaqMan® probe-based results for TTR. Average values of absolute CTs
(+/− SD) of triplicate wells for TTR obtained with SYBR® Green (grey) and
TaqMan® probe (white) detection methods in
BSE-infected samples are shown.
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Additional file 10: RT-qPCR analysis of blood specific marker RHAG.
CT values for the erythrocyte marker RHAG were monitored across
BSE-infected (solid fill) and non-infected (dotted fill) samples. Human
blood cDNA was used as positive control (gradient fill). Note that for
almost all the samples CT values were ≥ 35 therefore indicating a very
low expression level. Primer sequence (3’-5’): RHAG: F = AGGCAAGCTCAA
CATGGTTC, R = GGGTGAATTGCCATATCCGC.
Additional file 11: RT-qPCR analysis of blood specific marker
ALAS2. CT values for the erythrocyte marker ALAS2 were monitored
across BSE-infected (solid fill) and non-infected (dotted fill) samples.
Human blood cDNA was used as positive control (gradient fill). Note that
for almost all the samples CT values were≥ 35 therefore indicating a very
low expression level. Primer sequence (3’-5’): ALAS2: F = TCCCTTCA
TGCTGTCGGAAC, R = GAGCTAGGCAGATCTGTTTTGAA.
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